EUVIMEDEUVIMED entdecken
Crossref

Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis

Thomas Larive, Caroline Boursier, Marine Claudin, Jeanne Varlot, Laura Filippetti, Olivier Huttin, Véronique Roch, Laetitia Imbert, Matthieu Doyen, Aurélien Lambert, Damien Mandry, Zohra Lamiral und 2 weitere

Journal of Nuclear Medicine · 2024

DOI: 10.2967/jnumed.123.267219 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Nuclear Medicine, 2024. Verfasst von Thomas Larive und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nuclear Medicine, CHRU Nancy, Université de Lorraine, Nancy, France. Hauptthemen laut MEDLINE: Myocarditis, Myocardium, Octreotide, Somatostatin. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 28 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Myocardial somatostatin PET uptake is observed not only in most patients with acute myocarditis (AM) but also in some oncology patients referred for routine somatostatin PET. This raises concerns about the specificity of somatostatin PET for detecting myocarditis. The current study aims to identify factors associated with the detection of myocardial uptake on somatostatin PET scans recorded for oncology indications and differential PET criteria that characterize myocardial uptake in AM patients.

Methods

We analyzed factors associated with the detection of myocardial [68Ga]Ga-DOTATOC uptake in 508 [68Ga]Ga-DOTATOC PET scans from 178 patients, performed for confirmed or suspected oncologic disease (Onc-PET) and PET criteria that could differentiate myocardial [68Ga]Ga-DOTATOC uptake in 31 patients with MRI-ascertained AM (AM-PET) from that in the Onc-PET group.

Results

Significant myocardial uptake was detected in 137 (26.9%) Onc-PET scans and was independently associated with somatostatin analog treatment (exp(β), 0.805; 95% CI, 0.728-0.890; P < 0.001) and age (exp(β), 1.005; 95% CI, 1.001-1.009; P = 0.012). A comparable model was selected for predicting the myocardial-to-blood SUVmax ratio using somatostatin analog treatment (P < 0.001) and history of coronary artery disease (P = 0.022). Myocardial uptake was detected in 12.9% (25/193) of Onc-PET scans from patients treated with somatostatin analogs but in 43.4% (59/136) of untreated patients over the median age of 64 y. Myocardial uptake was apparent in all 31 AM-PET scans, with volume and intensity of uptake dramatically higher than in the 137 Onc-PET scans showing myocardial uptake. A myocardial-to-blood SUVmax ratio threshold of 2.20 provided a sensitivity of 87% (27/31) and a specificity of 88% (44/50) for differentiating myocardial uptake between the AM-PET group and an Onc-PET group restricted to patients with clinical characteristics comparable to those of patients in the AM-PET group (≤64 y of age, no coronary artery disease history, and no somatostatin agonists). A myocardial uptake volume threshold of 18 cm3 provided comparable diagnostic accuracy (sensitivity, 84% [26/31]; specificity, 94% [47/50]).

Conclusion

Myocardial uptake was detected in 26.9% of somatostatin PET scans recorded for oncology indications. This rate was decreased by somatostatin analog treatments and increased in older individuals. However, somatostatin PET scans, analyzed with the quantitative criterion of uptake intensity or volume, are able to identify AM and to differentiate it from myocardial uptake of other origins.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MyocarditisMyocardiumOctreotideSomatostatinAdultAgedFemaleHumansMaleMiddle AgedAcute DiseaseBiological TransportDiagnosis, DifferentialHeartNeoplasmsOrganometallic CompoundsPositron-Emission TomographyRadiopharmaceuticalsRetrospective Studies

Stichwörter der Autor:innen

PET[68Ga]Ga-DOTATOCacute myocarditismyocardial inflammationsomatostatin receptor

Substanzen

Ga(III)-DOTATOCOctreotideOrganometallic CompoundsRadiopharmaceuticalsSomatostatin

Autor:innen und Institutionen

  • Department of Nuclear Medicine, CHRU Nancy, Université de Lorraine, Nancy, France.
  • Nancyclotep Imaging Platform, CHRU Nancy, Université de Lorraine, Nancy, France.
  • UMR 1254, INSERM, Université de Lorraine, Nancy, France.
  • Department of Cardiology, CHRU Nancy, Nancy, France.
  • UMR 1116, INSERM, Université de Lorraine, Nancy, France.
  • Université de Lorraine, Nancy, France.

Zitieren

APA

Larive, T., Boursier, C., Claudin, M., Varlot, J., Filippetti, L., Huttin, O., Roch, V., Imbert, L., Doyen, M., Lambert, A., Mandry, D., Lamiral, Z., Chevalier, E., & Marie, P. Y. (2024). Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis. Journal of Nuclear Medicine. https://doi.org/10.2967/jnumed.123.267219

Vancouver

Larive T, Boursier C, Claudin M, Varlot J, Filippetti L, Huttin O, et al. Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis. Journal of Nuclear Medicine. 2024. doi:10.2967/jnumed.123.267219

BibTeX
@article{Larive2024,
  author = {Larive, Thomas and Boursier, Caroline and Claudin, Marine and Varlot, Jeanne and Filippetti, Laura and Huttin, Olivier and Roch, Véronique and Imbert, Laetitia and Doyen, Matthieu and Lambert, Aurélien and Mandry, Damien and Lamiral, Zohra and Chevalier, Elodie and Marie, Pierre-Yves},
  title = {Factors Associated with Myocardial Uptake on Oncologic Somatostatin PET Investigations and Differentiation from Myocardial Uptake of Acute Myocarditis},
  journal = {Journal of Nuclear Medicine},
  year = {2024},
  doi = {10.2967/jnumed.123.267219}
}
Kostenlos starten →